Ascendis Pharma: Skytrofa Net Sales Not The Update Investors Are Waiting For

PeopleImages

Ascendis Pharma A/S (ASND) reported strong sequential growth of Skytrofa in the third quarter and the company raised the full-year net sales guidance range from €165-170 million to €170-175 million.…

This data comes from the ChinaPulse.com media intelligence and smart news insights monitoring platform.